Our mission is to provide the world‘s most advanced service platform to unlock chemical matter and help to bring the most innovative medicines to patients. Since the inception of the company, we have successfully pioneered our “structural data first” approach to unlock untapped potential of difficult targets.
CRYSTALSFIRST® provides cutting-edge solutions to unlock chemical matter for protein targets. Our discovery platform and flexible business model have a proven track record of successful campaign with global pharma and biotech companies.
“CrystalsFirst’s platform significantly improved the crystallographic quality and unlocked the potential for a novel inhibition mechanism of our target of interest. Their team is distinguished by flexible problem skills and pro-active communication. We absolutely recommend CrystalsFirst’s expertise and services to other companies!”
“We are very impressed by the impact CrystalsFirst’s platform has had on our discovery efforts. Their structural biology and fragment screening technologies provided valuable insights that helped us advance our programs.”
“CrystalsFirst is a recognized expert in crystallographic fragment screening and co-structure determination to unlock chemical matter. The company has always focused on meeting our expectations, taking the time to understand the project and its complexities. We enjoyed collaborating with the CrystalsFirst team and recommend CrystalsFirst’s expertise and services to other companies.”
“CrystalsFirst is a recognized structural biology expert providing services for structure-based drug discovery. Their team was very accommodating, meeting very tight timelines of the project, and communicating proactively throughout the project. CrystalsFirst’s technology and distinguished problem-solving skills helped to determine co-structures where other companies had significant challenges. We enjoyed collaborating with the CrystalsFirst team and recommend CrystalsFirst’s expertise and services to other companies.”
“CrystalsFirst’s MAGNET platform exceeded our expectations by rapidly delivering high-resolution structural data, including novel mechanistic insights, to guide medicinal chemistry. We look forward to expanding our partnership with CrystalsFirst to leverage their platforms across even more targets.”